Umbilical cord mesenchymal stem cell exosomes
US-2015125950-A1 · May 7, 2015 · US
Composition for improving, preventing or treating skin diseases comprising induced pluripotent stem cell-derived mesenchymal stem cell and exosome derived therefrom
US11723931B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11723931-B2 |
| Application number | US-201916959175-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 7, 2019 |
| Priority date | Jan 5, 2018 |
| Publication date | Aug 15, 2023 |
| Grant date | Aug 15, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention may provide a pharmaceutical composition for preventing or treating skin diseases, a cosmetic composition for preventing or improving skin diseases, and a stem cell therapeutic agent, which comprise an induced pluripotent stem cell-derived mesenchymal stem cell (iMSC), a culture thereof, or an exosome isolated from an iMSC or iMSC culture as active ingredients. When the composition of the present invention, etc. is used, it is possible to provide a composition for improving, preventing or treating skin diseases and a stem cell therapeutic agent which have an improved immunomodulating function over conventional mesenchymal stem cells.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating or alleviating a skin disease in a subject in need thereof, comprising: administering to the subject a composition comprising an effective amount of one or more exosomes isolated from induced pluripotent stem cell-derived mesenchymal stem cells or a culture thereof, wherein the skin disease is selected from the group consisting of atopic dermatitis and contact dermatitis. 2. The method of claim 1 , wherein the subject is a mammal or a human.
Assignees
Inventors
Classifications
- A61K35/545Primary
Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells · CPC title
Reproductive organs; Embryos, Eggs · CPC title
Blood, e.g. plasma · CPC title
- A61K35/28Primary
Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title
Anti-acne agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11723931B2 cover?
- The present invention may provide a pharmaceutical composition for preventing or treating skin diseases, a cosmetic composition for preventing or improving skin diseases, and a stem cell therapeutic agent, which comprise an induced pluripotent stem cell-derived mesenchymal stem cell (iMSC), a culture thereof, or an exosome isolated from an iMSC or iMSC culture as active ingredients. When the co…
- Who is the assignee on this patent?
- Asan Found, Univ Ulsan Found Ind Coop
- What technology area does this patent fall under?
- Primary CPC classification A61K35/545. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 15 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).